Radiation improves long-term advantage in breast cancer:
This article was originally published in Clinica
Providing high-risk breast cancer patients with radiation therapy in addition to chemotherapy, may add significant benefit than just chemotherapy alone. So finds a 20-year study, published in Journal of the National Cancer Institute (January 19), which observed that patients who received radiation therapy and adjuvant chemotherapy, compared to chemotherapy alone, had significant improvements in breast cancer survival (48%, versus 30%) and overall survival (47%, versus 37%). All 318 pre-menopausal women enrolled on the study had previously been treated with modified radical mastectomy and lymph node removal.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.